{"diseaseContext":"triple-negative breast cancer","genes":[{"symbol":"BRCA1","name":"RING-type E3 ubiquitin transferase","function":"Function not well characterized","importanceScore":0.95,"centrality":1,"uniprotId":"A0A2R8Y7V5","tissueExpression":"Expression pattern not well characterized"},{"symbol":"EGFR","name":"Receptor protein-tyrosine kinase","function":"Function not well characterized","importanceScore":0.87,"centrality":0.7165313105737893,"uniprotId":"C9JYS6","tissueExpression":"Expression pattern not well characterized"},{"symbol":"TP53","name":"Cellular tumor antigen p53","function":"Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence. Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Negatively regulates...","importanceScore":0.7899999999999999,"centrality":0.513417119032592,"uniprotId":"S4R334","tissueExpression":"Expression pattern not well characterized"}],"pathways":[{"id":"pathway-0","name":"ErbB signaling pathway","rationale":"EGFR (ErbB-1) is a key driver of TNBC progression, metastasis, and therapeutic resistance, with overexpression observed in approximately 70% of TNBC patients.","significance":"EGFR (ErbB-1) is a key driver of TNBC progression, metastasis, and therapeutic resistance, with overexpression observed in approximately 70% of TNBC patients.","molecularMechanism":"Ligand binding induces EGFR homodimerization and autophosphorylation of specific tyrosine residues (e.g., Y1068, Y1173) in its cytoplasmic tail. This recruits adaptor proteins (Grb2, Shc) to activate the RAS-RAF-MEK-ERK cascade and PI3K-AKT-mTOR pathway. EGFR also transactivates downstream transcription factors like STAT3.","regulation":"Upstream: Ligands (EGF, TGF-α), GPCRs (e.g., GnRHR via PKC/EGFR transactivation). Downstream: MAPK (ERK1/2), PI3K-AKT-mTOR, STAT3, SRC kinases.","experimentalEvidence":"Validated in TNBC cell lines (MDA-MB-231, MDA-MB-468) and patient-derived xenografts (PDX). EGFR overexpression confirmed by multiplex immunofluorescence in 104 TNBC patient specimens.","quantitativeData":"EGFR overexpression in ~70% of TNBC patients; PCSK9 reduces plasma membrane cholesterol to activate EGFR and HER3; STAT3/miR-221-3p/Fascin-1 axis implicated in EGFR TKI resistance.","consensusMetrics":"Well-established (supported by 8+ papers in provided literature, including reviews and primary research).","controversies":"Well-established role in TNBC, but debate exists on the efficacy of monotherapy EGFR inhibitors due to compensatory pathway activation.","score":0.7,"pvalue":0.0061374011151250005,"citations":["PMID:38900236","PMID:38145448","PMID:38604999","PMID:40192514","PMID:40806559"],"confidence":"medium"},{"id":"pathway-1","name":"PD-L1 expression and PD-1 checkpoint pathway in cancer","rationale":"Critical for TNBC immune evasion; targeting this pathway is a major immunotherapeutic strategy, though response rates are variable.","significance":"Critical for TNBC immune evasion; targeting this pathway is a major immunotherapeutic strategy, though response rates are variable.","molecularMechanism":"Upregulation of PD-L1 on TNBC cells is driven by pro-survival pathways: MAPK and PI3K/Akt activation, and transcription factors HIF-1, STAT3, and NF-κB. Tumor cell surface PD-L1 engages PD-1 on T cells, delivering an inhibitory signal that suppresses TCR-mediated activation, proliferation, and cytokine production.","regulation":"Upstream: Oncogenic signaling (EGFR, PI3K/Akt), hypoxia (HIF-1α), inflammatory cytokines (via STAT3/NF-κB). Downstream: Inhibition of T cell receptor (TCR) signaling, reduced cytokine production (IFN-γ, IL-2).","experimentalEvidence":"Mechanism supported by pathway databases; clinical use of anti-PD-1/PD-L1 antibodies (e.g., pembrolizumab) in TNBC is established.","quantitativeData":"Not reported in abstracts (pathway description is generic from KEGG).","consensusMetrics":"Well-established mechanism; clinical efficacy in TNBC is an active area of research.","controversies":"Paclitaxel + anti-PD-1/PD-L1 benefits only a small proportion of metastatic TNBC patients, highlighting need for better predictive biomarkers.","score":0.5,"pvalue":0.007182733824,"citations":["PMID:39085861"],"confidence":"low"},{"id":"pathway-2","name":"Central carbon metabolism in cancer","rationale":"TNBC exhibits metabolic reprogramming (Warburg effect, glutaminolysis) to support rapid proliferation, biomass duplication, and survival under stress.","significance":"TNBC exhibits metabolic reprogramming (Warburg effect, glutaminolysis) to support rapid proliferation, biomass duplication, and survival under stress.","molecularMechanism":"Oncogenic signaling (e.g., via EGFR/PI3K/Akt, mutant TP53) upregulates glycolysis and glutaminolysis. Key regulators include transcription factors c-MYC, HIF-1, and p53. Intermediates from these pathways feed into macromolecule synthesis (nucleotides, lipids, proteins).","regulation":"Upstream: EGFR/PI3K/AKT, mutant TP53, hypoxia (HIF-1α). Downstream: Enzymes of glycolysis (HK2, PKM2), glutaminolysis (GLS), PPP, and TCA cycle.","experimentalEvidence":"Descriptive from KEGG; supported by general cancer biology. Recent TNBC literature identifies specific metabolic targets (e.g., ATP5MF, choline metabolism).","quantitativeData":"Not reported in abstracts (pathway description is generic from KEGG).","consensusMetrics":"Well-established cancer hallmark; specific targets in TNBC are emerging.","controversies":"Well-established","score":0.5,"pvalue":0.008823918172375,"citations":["PMID:39402579"],"confidence":"low"},{"id":"pathway-3","name":"EGFR tyrosine kinase inhibitor resistance","rationale":"A major clinical obstacle in TNBC, limiting the efficacy of EGFR-targeted therapies like erlotinib.","significance":"A major clinical obstacle in TNBC, limiting the efficacy of EGFR-targeted therapies like erlotinib.","molecularMechanism":"Resistance mechanisms include: 1) Secondary EGFR mutation (T790M), 2) Activation of alternative pathways (c-Met/HGF, AXL), 3) Aberrant downstream signaling (K-RAS mutations, PTEN loss), 4) Impaired apoptosis (BIM deletion polymorphism), 5) Histologic transformation.","regulation":"Upstream: Genetic alterations, compensatory pathway activation. Downstream: Sustained MAPK/PI3K signaling despite EGFR inhibition.","experimentalEvidence":"Mechanisms defined in lung cancer and other malignancies; relevance to TNBC is supported by studies on erlotinib resistance.","quantitativeData":"PDZK1 sensitizes TNBC cells to erlotinib via the EGFR pathway; STAT3/miR-221-3p/Fascin-1 axis implicated in resistance.","consensusMetrics":"Emerging evidence in TNBC (2-3 papers), but well-established in other cancers.","controversies":"Well-established","score":0.7,"pvalue":0.010612237238875,"citations":["PMID:38145448","PMID:38604999"],"confidence":"medium"}],"topics":[{"id":"topic-0","theme":"Targeting EGFR and its downstream pathways in TNBC","summary":"EGFR remains a prime therapeutic target in TNBC due to its frequent overexpression and role in driving aggressive phenotypes, but monotherapies are limited by resistance, leading to exploration of combination strategies, ADCs, and targeting downstream effectors.","keyFindings":[],"citations":["PMID:38900236","PMID:38145448","PMID:38604999","PMID:40192514","PMID:40806559","PMID:38772416"]},{"id":"topic-1","theme":"Overcoming therapeutic resistance in TNBC","summary":"A major focus is understanding and overcoming intrinsic and acquired resistance to targeted therapies (e.g., EGFR TKIs, PARP inhibitors) and chemotherapy through combination strategies and novel targets.","keyFindings":[],"citations":["PMID:38145448","PMID:39572842","PMID:38981022","PMID:38604999"]},{"id":"topic-2","theme":"Exploiting metabolic vulnerabilities and immune modulation","summary":"Research explores targeting TNBC's unique metabolic dependencies (Warburg effect, choline metabolism) and overcoming its immunosuppressive microenvironment to enhance therapy.","keyFindings":[],"citations":["PMID:39402579","PMID:39085861"]}],"strategies":[{"id":"strategy-0","label":"EGFR-targeted therapy with Tyrosine Kinase Inhibitors (TKIs)","rationale":"EGFR is highly expressed in most TNBC patients and drives proliferation and metastasis via the PI3K/Akt/mTOR pathway.","molecularTarget":"Inhibition of EGFR tyrosine kinase activity (e.g., by erlotinib) to block downstream MAPK and PI3K/Akt signaling.","clinicalEvidence":"Used in clinical trials for TNBC, but limited patient benefit due to resistance.","experimentalSupport":"PDZK1 suppresses TNBC and sensitizes cells to erlotinib in vitro/in vivo. Ononin inhibits TNBC lung metastasis by targeting EGFR-mediated PI3K/Akt/mTOR.","limitations":"Only a small proportion of TNBC patients benefit in clinical trials due to intrinsic/acquired resistance mechanisms (e.g., alternative pathway activation).","quantitativeData":"Ononin inhibits TNBC lung metastasis by targeting EGFR-mediated PI3K/Akt/mTOR pathway; PDZK1 sensitizes TNBC cells to erlotinib.","trialData":"No trial data in abstracts","biomarkerInfo":"Biomarker not specified (likely EGFR expression, but not detailed in abstracts).","riskLevel":"medium","citations":["PMID:38900236","PMID:38604999"],"confidence":"medium"},{"id":"strategy-1","label":"Anti-EGFR Antibody-Drug Conjugate (ADC)","rationale":"To deliver a potent cytotoxic agent or pathway inhibitor directly to EGFR-overexpressing TNBC cells, overcoming limitations of naked antibodies or TKIs.","molecularTarget":"Anti-EGFR antibody (e.g., cetuximab) conjugated to a cytotoxic payload or a CDK inhibitor.","clinicalEvidence":"Preclinical stage; anti-EGFR antibodies alone show limited response.","experimentalSupport":"An anti-EGFR ADC carrying a CDK inhibitor restricts TNBC growth in preclinical models, potentially overcoming compensatory pathway activation.","limitations":"Anti-EGFR antibodies show limited monotherapy response, partly due to compensatory pathway activation.","quantitativeData":"Anti-EGFR ADC carrying a CDK inhibitor restricts TNBC growth.","trialData":"No trial data in abstracts","biomarkerInfo":"Likely requires EGFR overexpression, but not specified.","riskLevel":"medium","citations":["PMID:38772416"],"confidence":"low"},{"id":"strategy-2","label":"PARP inhibitor combination therapy in BRCA-mutated TNBC","rationale":"BRCA mutations impair homologous recombination repair (HRR). PARP inhibition traps PARP on DNA, causing replication fork collapse and double-strand breaks that cannot be repaired in HRR-deficient cells.","molecularTarget":"Poly(ADP-ribose) polymerase (PARP) enzymes, inducing synthetic lethality in BRCA1/2-deficient cells.","clinicalEvidence":"PARP inhibitors (e.g., olaparib) are FDA-approved for germline BRCA-mutated HER2-negative metastatic breast cancer. Combination strategies aim to overcome resistance.","experimentalSupport":"Review discusses combination strategies with PARP inhibitors to overcome resistance mechanisms in BRCA-mutated TNBC.","limitations":"Development of resistance is common (e.g., via BRCA reversion mutations, restoration of HRR).","quantitativeData":"Not reported in abstracts","trialData":"No specific trial data in abstracts","biomarkerInfo":"Germline BRCA1/2 mutation required; prevalence in TNBC: ~15-20%.","riskLevel":"low","citations":["PMID:39572842"],"confidence":"medium"},{"id":"strategy-3","label":"CDK9 inhibition combined with EGFR inhibition","rationale":"CDK9 is involved in transcriptional addiction in TNBC. Its disruption suppresses TNBC, and efficacy is enhanced by concurrent EGFR inhibition, potentially blocking compensatory survival signals.","molecularTarget":"Cyclin-dependent kinase 9 (CDK9), which phosphorylates RNA Pol II CTD to promote transcriptional elongation, often dysregulated in 'transcriptional addiction' in cancer.","clinicalEvidence":"Preclinical stage.","experimentalSupport":"Disrupting CDK9 activity suppresses TNBC in preclinical models, and this effect is enhanced by EGFR inhibition.","limitations":"Preclinical evidence only; potential toxicity from global transcriptional inhibition.","quantitativeData":"Disrupting CDK9 activity suppresses TNBC and is enhanced by EGFR Inhibition.","trialData":"No trial data in abstracts","biomarkerInfo":"Biomarker not specified","riskLevel":"high","citations":["PMID:41505030"],"confidence":"low"},{"id":"hypothesis-0","label":"Novel hypothesis: CircCFL1 promotes TNBC stemness and immunoescape by regulating mutant TP53 transcription via a deacetylation-mediated mechanism affecting c-Myc stability.","riskLevel":"high","citations":["PMID:38981022"],"confidence":"low","isHypothesis":true}],"interactions":{"totalInteractions":30,"avgConfidence":"0.001","topInteractors":[{"gene":"TP53","partner":"EP300","partnerName":"Unknown protein","confidence":0.001,"confidenceLevel":"low","sources":["STRING"],"validated":false,"evidenceCount":3,"evidenceTypes":[{"type":"experiments","score":0.964,"sources":1},{"type":"databases","score":0.5,"sources":1},{"type":"textmining","score":0.982,"sources":1}]},{"gene":"TP53","partner":"CREBBP","partnerName":"Unknown protein","confidence":0.001,"confidenceLevel":"low","sources":["STRING"],"validated":false,"evidenceCount":3,"evidenceTypes":[{"type":"experiments","score":0.96,"sources":1},{"type":"databases","score":0.7,"sources":1},{"type":"textmining","score":0.982,"sources":1}]},{"gene":"TP53","partner":"BCL2L1","partnerName":"Unknown protein","confidence":0.001,"confidenceLevel":"low","sources":["STRING"],"validated":false,"evidenceCount":2,"evidenceTypes":[{"type":"experiments","score":0.955,"sources":1},{"type":"textmining","score":0.982,"sources":1}]},{"gene":"TP53","partner":"MDM2","partnerName":"Unknown protein","confidence":0.001,"confidenceLevel":"low","sources":["STRING"],"validated":false,"evidenceCount":3,"evidenceTypes":[{"type":"experiments","score":0.964,"sources":1},{"type":"databases","score":0.7,"sources":1},{"type":"textmining","score":0.983,"sources":1}]},{"gene":"TP53","partner":"MDM4","partnerName":"Unknown protein","confidence":0.001,"confidenceLevel":"low","sources":["STRING"],"validated":false,"evidenceCount":3,"evidenceTypes":[{"type":"experiments","score":0.96,"sources":1},{"type":"databases","score":0.7,"sources":1},{"type":"textmining","score":0.983,"sources":1}]},{"gene":"TP53","partner":"BCL2","partnerName":"Unknown protein","confidence":0.001,"confidenceLevel":"low","sources":["STRING"],"validated":false,"evidenceCount":3,"evidenceTypes":[{"type":"experiments","score":0.618,"sources":1},{"type":"databases","score":0.9,"sources":1},{"type":"textmining","score":0.982,"sources":1}]},{"gene":"TP53","partner":"TP53BP2","partnerName":"Unknown protein","confidence":0.001,"confidenceLevel":"low","sources":["STRING"],"validated":false,"evidenceCount":3,"evidenceTypes":[{"type":"experiments","score":0.96,"sources":1},{"type":"databases","score":0.5,"sources":1},{"type":"textmining","score":0.982,"sources":1}]},{"gene":"TP53","partner":"TP53BP1","partnerName":"Unknown protein","confidence":0.001,"confidenceLevel":"low","sources":["STRING"],"validated":false,"evidenceCount":2,"evidenceTypes":[{"type":"experiments","score":0.96,"sources":1},{"type":"textmining","score":0.982,"sources":1}]},{"gene":"TP53","partner":"HTT","partnerName":"Unknown protein","confidence":0.001,"confidenceLevel":"low","sources":["STRING"],"validated":false,"evidenceCount":3,"evidenceTypes":[{"type":"experiments","score":0.307,"sources":1},{"type":"databases","score":0.8,"sources":1},{"type":"textmining","score":0.979,"sources":1}]},{"gene":"TP53","partner":"PPP1R13L","partnerName":"Unknown protein","confidence":0.001,"confidenceLevel":"low","sources":["STRING"],"validated":false,"evidenceCount":3,"evidenceTypes":[{"type":"experiments","score":0.96,"sources":1},{"type":"databases","score":0.5,"sources":1},{"type":"textmining","score":0.783,"sources":1}]}],"networkHubs":[{"gene":"TP53","centrality":1},{"gene":"BRCA1","centrality":0.8333333333333334},{"gene":"ABRAXAS2","centrality":0.3333333333333333},{"gene":"FANCC","centrality":0.3333333333333333},{"gene":"EGFR","centrality":0.3333333333333333}],"networkImageUrl":"https://string-db.org/api/image/network?identifiers=BRCA1%0AEGFR%0ATP53&species=9606&required_score=700&network_flavor=confidence&hide_disconnected_nodes=1"},"network3DData":{"nodes":[{"id":"BRCA1","name":"RING-type E3 ubiquitin transferase","group":0,"importance":0.95,"val":12.5,"isPrimary":true,"isHub":true,"centrality":0.8333333333333334},{"id":"EGFR","name":"Receptor protein-tyrosine kinase","group":0,"importance":0.87,"val":5,"isPrimary":true,"isHub":true,"centrality":0.3333333333333333},{"id":"TP53","name":"Cellular tumor antigen p53","group":0,"importance":0.7899999999999999,"val":15,"isPrimary":true,"isHub":true,"centrality":1},{"id":"EP300","name":"EP300","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"CREBBP","name":"CREBBP","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"BCL2L1","name":"BCL2L1","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"MDM2","name":"MDM2","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"MDM4","name":"MDM4","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"BCL2","name":"BCL2","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"TP53BP2","name":"TP53BP2","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"TP53BP1","name":"TP53BP1","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"HTT","name":"HTT","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"PPP1R13L","name":"PPP1R13L","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"ABRAXAS1","name":"ABRAXAS1","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"BABAM2","name":"BABAM2","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"BARD1","name":"BARD1","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"UIMC1","name":"UIMC1","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"PALB2","name":"PALB2","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"BRIP1","name":"BRIP1","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"BABAM1","name":"BABAM1","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"BRCC3","name":"BRCC3","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"RBBP8","name":"RBBP8","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"RAD51","name":"RAD51","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"CBL","name":"CBL","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"TGFA","name":"TGFA","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"EREG","name":"EREG","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"GRB2","name":"GRB2","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"HBEGF","name":"HBEGF","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"EPGN","name":"EPGN","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"ERBB3","name":"ERBB3","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"ERBB2","name":"ERBB2","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"EGF","name":"EGF","group":1,"importance":0.3,"val":5,"isPrimary":false},{"id":"DCN","name":"DCN","group":1,"importance":0.3,"val":5,"isPrimary":false}],"links":[{"source":"TP53","target":"EP300","value":0.001,"label":"0% confidence","discoveryYear":2018},{"source":"TP53","target":"CREBBP","value":0.001,"label":"0% confidence","discoveryYear":2015},{"source":"TP53","target":"BCL2L1","value":0.001,"label":"0% confidence","discoveryYear":2025},{"source":"TP53","target":"MDM2","value":0.001,"label":"0% confidence","discoveryYear":2015},{"source":"TP53","target":"MDM4","value":0.001,"label":"0% confidence","discoveryYear":2018},{"source":"TP53","target":"BCL2","value":0.001,"label":"0% confidence","discoveryYear":2022},{"source":"TP53","target":"TP53BP2","value":0.001,"label":"0% confidence","discoveryYear":2022},{"source":"TP53","target":"TP53BP1","value":0.001,"label":"0% confidence","discoveryYear":2024},{"source":"TP53","target":"HTT","value":0.001,"label":"0% confidence","discoveryYear":2018},{"source":"TP53","target":"PPP1R13L","value":0.001,"label":"0% confidence","discoveryYear":2021},{"source":"BRCA1","target":"ABRAXAS1","value":0.001,"label":"0% confidence","discoveryYear":2021},{"source":"BRCA1","target":"BABAM2","value":0.001,"label":"0% confidence","discoveryYear":2025},{"source":"BRCA1","target":"BARD1","value":0.001,"label":"0% confidence","discoveryYear":2023},{"source":"BRCA1","target":"UIMC1","value":0.001,"label":"0% confidence","discoveryYear":2018},{"source":"BRCA1","target":"PALB2","value":0.001,"label":"0% confidence","discoveryYear":2016},{"source":"BRCA1","target":"BRIP1","value":0.001,"label":"0% confidence","discoveryYear":2015},{"source":"BRCA1","target":"BABAM1","value":0.001,"label":"0% confidence","discoveryYear":2015},{"source":"BRCA1","target":"BRCC3","value":0.001,"label":"0% confidence","discoveryYear":2021},{"source":"BRCA1","target":"RBBP8","value":0.001,"label":"0% confidence","discoveryYear":2021},{"source":"BRCA1","target":"RAD51","value":0.001,"label":"0% confidence","discoveryYear":2022},{"source":"EGFR","target":"CBL","value":0.001,"label":"0% confidence","discoveryYear":2025},{"source":"EGFR","target":"TGFA","value":0.001,"label":"0% confidence","discoveryYear":2024},{"source":"EGFR","target":"EREG","value":0.001,"label":"0% confidence","discoveryYear":2016},{"source":"EGFR","target":"GRB2","value":0.001,"label":"0% confidence","discoveryYear":2019},{"source":"EGFR","target":"HBEGF","value":0.001,"label":"0% confidence","discoveryYear":2020},{"source":"EGFR","target":"EPGN","value":0.001,"label":"0% confidence","discoveryYear":2017},{"source":"EGFR","target":"ERBB3","value":0.001,"label":"0% confidence","discoveryYear":2015},{"source":"EGFR","target":"ERBB2","value":0.001,"label":"0% confidence","discoveryYear":2021},{"source":"EGFR","target":"EGF","value":0.001,"label":"0% confidence","discoveryYear":2024},{"source":"EGFR","target":"DCN","value":0.001,"label":"0% confidence","discoveryYear":2020}],"stats":{"totalNodes":33,"totalLinks":30,"avgConfidence":"0.00","hubCount":3}},"clinical":{"totalAssociations":0,"avgScore":0,"highConfidence":0,"topAssociations":[],"sharedDiseases":[]},"drugs":{"totalCompounds":725,"totalApproved":0,"avgPotency":7.27,"phaseDistribution":{"approved":209,"phase3":0,"phase2":1,"phase1":497,"preclinical":0},"topCompounds":[{"chemblId":"CHEMBL2110732","name":"DACOMITINIB ANHYDROUS","maxPhase":"4.0","phaseLabel":"Unknown","molecularWeight":"469.95","activityType":"IC50","activityValue":"5.8","activityUnits":"nmol/L","pChEMBL":"8.24","potency":"high","assayDescription":"Inhibition of EGFR expressed in mouse NIH3T3 cells","pubmedId":"CHEMBL5661976","gene":"EGFR","source":"ChEMBL","targetId":"CHEMBL3608","genes":["EGFR"],"sources":["ChEMBL"],"validated":"single-source","targetsMultipleGenes":false},{"chemblId":"CHEMBL3353410","name":"OSIMERTINIB","maxPhase":"4.0","phaseLabel":"Unknown","molecularWeight":"499.62","activityType":"IC50","activityValue":"0.009","activityUnits":"uM","pChEMBL":"8.05","potency":"high","assayDescription":"Inhibition of wild type EGFR in mouse BaF3 cells assessed as cell growth inhibition measured after 72 hrs by CellTiter-Glo assay","pubmedId":"CHEMBL5329204","gene":"EGFR","source":"ChEMBL","targetId":"CHEMBL3608","genes":["EGFR"],"sources":["ChEMBL"],"validated":"single-source","targetsMultipleGenes":false},{"chemblId":"CHEMBL939","name":"GEFITINIB","maxPhase":"4.0","phaseLabel":"Unknown","molecularWeight":"446.91","activityType":"IC50","activityValue":"14.4","activityUnits":"nmol/L","pChEMBL":"7.84","potency":"high","assayDescription":"Inhibition of EGFR expressed in mouse NIH3T3 cells","pubmedId":"CHEMBL5661976","gene":"EGFR","source":"ChEMBL","targetId":"CHEMBL3608","genes":["EGFR"],"sources":["ChEMBL"],"validated":"single-source","targetsMultipleGenes":false},{"chemblId":"CHEMBL553","name":"ERLOTINIB","maxPhase":"4.0","phaseLabel":"Unknown","molecularWeight":"393.44","activityType":"IC50","activityValue":"19.3","activityUnits":"nmol/L","pChEMBL":"7.71","potency":"high","assayDescription":"Inhibition of EGFR expressed in mouse NIH3T3 cells","pubmedId":"CHEMBL5661976","gene":"EGFR","source":"ChEMBL","targetId":"CHEMBL3608","genes":["EGFR"],"sources":["ChEMBL"],"validated":"single-source","targetsMultipleGenes":false},{"name":"CARBOPLATIN","chemblId":"rxcui:40048","maxPhase":4,"phaseLabel":"FDA Approved","pChEMBL":null,"potency":"Interaction: Unknown","sources":["DGIdb"],"validated":"single-source","sourceCount":2,"pmids":[],"genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1"],"approvalStatus":"approved","isApproved":true,"gene":"BRCA1","source":"DGIdb","targetId":null,"targetsMultipleGenes":true},{"name":"PACLITAXEL","chemblId":"rxcui:56946","maxPhase":4,"phaseLabel":"FDA Approved","pChEMBL":null,"potency":"Interaction: Unknown","sources":["DGIdb"],"validated":"single-source","sourceCount":1,"pmids":[12684687],"genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1"],"approvalStatus":"approved","isApproved":true,"gene":"BRCA1","source":"DGIdb","targetId":null,"targetsMultipleGenes":true},{"name":"CISPLATIN","chemblId":"rxcui:2555","maxPhase":4,"phaseLabel":"FDA Approved","pChEMBL":null,"potency":"Interaction: Unknown","sources":["DGIdb"],"validated":"single-source","sourceCount":4,"pmids":[16982732],"genes":["BRCA1","EGFR","TP53"],"targets":["BRCA1"],"approvalStatus":"approved","isApproved":true,"gene":"BRCA1","source":"DGIdb","targetId":null,"targetsMultipleGenes":true},{"name":"DOXORUBICIN HYDROCHLORIDE","chemblId":"rxcui:142433","maxPhase":4,"phaseLabel":"FDA Approved","pChEMBL":null,"potency":"Interaction: Unknown","sources":["DGIdb"],"validated":"single-source","sourceCount":2,"pmids":[12698198],"genes":["BRCA1","TP53"],"targets":["BRCA1"],"approvalStatus":"approved","isApproved":true,"gene":"BRCA1","source":"DGIdb","targetId":null,"targetsMultipleGenes":true},{"name":"TALAZOPARIB","chemblId":"rxcui:2099704","maxPhase":4,"phaseLabel":"FDA Approved","pChEMBL":null,"potency":"Interaction: Unknown","sources":["DGIdb"],"validated":"single-source","sourceCount":4,"pmids":[],"genes":["BRCA1","EGFR"],"targets":["BRCA1"],"approvalStatus":"approved","isApproved":true,"gene":"BRCA1","source":"DGIdb","targetId":null,"targetsMultipleGenes":true},{"name":"TAMOXIFEN","chemblId":"rxcui:10324","maxPhase":4,"phaseLabel":"FDA Approved","pChEMBL":null,"potency":"Interaction: Unknown","sources":["DGIdb"],"validated":"single-source","sourceCount":2,"pmids":[15750629,11130383,16636335,16331614,15197194],"genes":["BRCA1","TP53"],"targets":["BRCA1"],"approvalStatus":"approved","isApproved":true,"gene":"BRCA1","source":"DGIdb","targetId":null,"targetsMultipleGenes":true}],"approvedDrugs":[],"multiTargetCompounds":[{"name":"CARBOPLATIN","chemblId":"rxcui:40048","targets":["BRCA1","EGFR","TP53"],"targetCount":3,"phase":"FDA Approved","potency":"Interaction: Unknown","pChEMBL":null,"role":"pan-inhibitor"},{"name":"PACLITAXEL","chemblId":"rxcui:56946","targets":["BRCA1","EGFR","TP53"],"targetCount":3,"phase":"FDA Approved","potency":"Interaction: Unknown","pChEMBL":null,"role":"pan-inhibitor"},{"name":"CISPLATIN","chemblId":"rxcui:2555","targets":["BRCA1","EGFR","TP53"],"targetCount":3,"phase":"FDA Approved","potency":"Interaction: Unknown","pChEMBL":null,"role":"pan-inhibitor"},{"name":"DOXORUBICIN HYDROCHLORIDE","chemblId":"rxcui:142433","targets":["BRCA1","TP53"],"targetCount":2,"phase":"FDA Approved","potency":"Interaction: Unknown","pChEMBL":null,"role":"pan-inhibitor"},{"name":"TALAZOPARIB","chemblId":"rxcui:2099704","targets":["BRCA1","EGFR"],"targetCount":2,"phase":"FDA Approved","potency":"Interaction: Unknown","pChEMBL":null,"role":"pan-inhibitor"}]},"drugRepurposing":{"candidates":[{"drug":"CARBOPLATIN","drugId":"rxcui:40048","repurposingScore":45,"confidence":"medium","breakdown":{"targetMatch":33.33333333333333,"pathwayOverlap":0,"clinicalEvidence":100,"safetyProfile":100,"mechanismRelevance":0},"matchedTargets":["BRCA1"],"currentIndication":"Unknown","proposedIndication":"triple-negative breast cancer","mechanism":"Not specified","phase":"FDA Approved","estimatedSavings":{"cost":"$1035M - $1535M","time":"8 - 10 years faster","confidence":"medium"},"reasoning":["⚠️ Partial target match (33%)","✅ FDA approved with proven safety profile"]},{"drug":"PACLITAXEL","drugId":"rxcui:56946","repurposingScore":45,"confidence":"medium","breakdown":{"targetMatch":33.33333333333333,"pathwayOverlap":0,"clinicalEvidence":100,"safetyProfile":100,"mechanismRelevance":0},"matchedTargets":["BRCA1"],"currentIndication":"Unknown","proposedIndication":"triple-negative breast cancer","mechanism":"Not specified","phase":"FDA Approved","estimatedSavings":{"cost":"$1035M - $1535M","time":"8 - 10 years faster","confidence":"medium"},"reasoning":["⚠️ Partial target match (33%)","✅ FDA approved with proven safety profile"]},{"drug":"CISPLATIN","drugId":"rxcui:2555","repurposingScore":45,"confidence":"medium","breakdown":{"targetMatch":33.33333333333333,"pathwayOverlap":0,"clinicalEvidence":100,"safetyProfile":100,"mechanismRelevance":0},"matchedTargets":["BRCA1"],"currentIndication":"Unknown","proposedIndication":"triple-negative breast cancer","mechanism":"Not specified","phase":"FDA Approved","estimatedSavings":{"cost":"$1035M - $1535M","time":"8 - 10 years faster","confidence":"medium"},"reasoning":["⚠️ Partial target match (33%)","✅ FDA approved with proven safety profile"]},{"drug":"DOXORUBICIN HYDROCHLORIDE","drugId":"rxcui:142433","repurposingScore":45,"confidence":"medium","breakdown":{"targetMatch":33.33333333333333,"pathwayOverlap":0,"clinicalEvidence":100,"safetyProfile":100,"mechanismRelevance":0},"matchedTargets":["BRCA1"],"currentIndication":"Unknown","proposedIndication":"triple-negative breast cancer","mechanism":"Not specified","phase":"FDA Approved","estimatedSavings":{"cost":"$1035M - $1535M","time":"8 - 10 years faster","confidence":"medium"},"reasoning":["⚠️ Partial target match (33%)","✅ FDA approved with proven safety profile"]},{"drug":"TALAZOPARIB","drugId":"rxcui:2099704","repurposingScore":45,"confidence":"medium","breakdown":{"targetMatch":33.33333333333333,"pathwayOverlap":0,"clinicalEvidence":100,"safetyProfile":100,"mechanismRelevance":0},"matchedTargets":["BRCA1"],"currentIndication":"Unknown","proposedIndication":"triple-negative breast cancer","mechanism":"Not specified","phase":"FDA Approved","estimatedSavings":{"cost":"$1035M - $1535M","time":"8 - 10 years faster","confidence":"medium"},"reasoning":["⚠️ Partial target match (33%)","✅ FDA approved with proven safety profile"]},{"drug":"TAMOXIFEN","drugId":"rxcui:10324","repurposingScore":45,"confidence":"medium","breakdown":{"targetMatch":33.33333333333333,"pathwayOverlap":0,"clinicalEvidence":100,"safetyProfile":100,"mechanismRelevance":0},"matchedTargets":["BRCA1"],"currentIndication":"Unknown","proposedIndication":"triple-negative breast cancer","mechanism":"Not specified","phase":"FDA Approved","estimatedSavings":{"cost":"$1035M - $1535M","time":"8 - 10 years faster","confidence":"medium"},"reasoning":["⚠️ Partial target match (33%)","✅ FDA approved with proven safety profile"]},{"drug":"DAUNORUBICIN HYDROCHLORIDE","drugId":"rxcui:81992","repurposingScore":45,"confidence":"medium","breakdown":{"targetMatch":33.33333333333333,"pathwayOverlap":0,"clinicalEvidence":100,"safetyProfile":100,"mechanismRelevance":0},"matchedTargets":["BRCA1"],"currentIndication":"Unknown","proposedIndication":"triple-negative breast cancer","mechanism":"Not specified","phase":"FDA Approved","estimatedSavings":{"cost":"$1035M - $1535M","time":"8 - 10 years faster","confidence":"medium"},"reasoning":["⚠️ Partial target match (33%)","✅ FDA approved with proven safety profile"]},{"drug":"MITOMYCIN","drugId":"rxcui:632","repurposingScore":45,"confidence":"medium","breakdown":{"targetMatch":33.33333333333333,"pathwayOverlap":0,"clinicalEvidence":100,"safetyProfile":100,"mechanismRelevance":0},"matchedTargets":["BRCA1"],"currentIndication":"Unknown","proposedIndication":"triple-negative breast cancer","mechanism":"Not specified","phase":"FDA Approved","estimatedSavings":{"cost":"$1035M - $1535M","time":"8 - 10 years faster","confidence":"medium"},"reasoning":["⚠️ Partial target match (33%)","✅ FDA approved with proven safety profile"]},{"drug":"MITOXANTRONE","drugId":"rxcui:7005","repurposingScore":45,"confidence":"medium","breakdown":{"targetMatch":33.33333333333333,"pathwayOverlap":0,"clinicalEvidence":100,"safetyProfile":100,"mechanismRelevance":0},"matchedTargets":["BRCA1"],"currentIndication":"Unknown","proposedIndication":"triple-negative breast cancer","mechanism":"Not specified","phase":"FDA Approved","estimatedSavings":{"cost":"$1035M - $1535M","time":"8 - 10 years faster","confidence":"medium"},"reasoning":["⚠️ Partial target match (33%)","✅ FDA approved with proven safety profile"]},{"drug":"RESVERATROL","drugId":"rxcui:1000492","repurposingScore":45,"confidence":"medium","breakdown":{"targetMatch":33.33333333333333,"pathwayOverlap":0,"clinicalEvidence":100,"safetyProfile":100,"mechanismRelevance":0},"matchedTargets":["BRCA1"],"currentIndication":"Unknown","proposedIndication":"triple-negative breast cancer","mechanism":"Not specified","phase":"FDA Approved","estimatedSavings":{"cost":"$1035M - $1535M","time":"8 - 10 years faster","confidence":"medium"},"reasoning":["⚠️ Partial target match (33%)","✅ FDA approved with proven safety profile"]}],"stats":{"totalDrugsAnalyzed":725,"candidatesFound":10,"avgScore":45,"analysisTime":"7ms","minScore":30,"onlyApproved":false},"summary":{"headline":"10 drug repurposing candidates identified for triple-negative breast cancer","summary":"Top candidate: CARBOPLATIN (45% match). 10 FDA-approved drugs found.","recommendation":"Prioritize CARBOPLATIN for experimental validation. Estimated savings: $1035M - $1535M vs. new drug development.","commercialValue":"Enterprise feature worth $10K-50K/year. Total potential savings across 10 candidates: $15000M - $25000M."},"enterpriseValue":"$10K-50K/year","timestamp":"2026-01-12T03:41:52.736Z"},"novelHypotheses":null,"citations":[{"pmid":"38735837","citation":"Yan Q, Deng Y, Zhang Q. A comprehensive overview of metaplastic breast cancer: Features and treatments.. Cancer science. 2024.","url":"https://pubmed.ncbi.nlm.nih.gov/38735837/"},{"pmid":"39500221","citation":"Sun L, Jia X, Wang K. Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes.. Breast (Edinburgh, Scotland). 2024.","url":"https://pubmed.ncbi.nlm.nih.gov/39500221/"},{"pmid":"40003864","citation":"Nedeljković M, Vuletić A, Mirjačić Martinović K. Divide and Conquer-Targeted Therapy for Triple-Negative Breast Cancer.. International journal of molecular sciences. 2025.","url":"https://pubmed.ncbi.nlm.nih.gov/40003864/"},{"pmid":"38900236","citation":"Ganesan K, Xu C, Wu J. Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.. Science China. Life sciences. 2024.","url":"https://pubmed.ncbi.nlm.nih.gov/38900236/"},{"pmid":"38502143","citation":"Kim J, Fahmy V, Haffty BG. Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives.. Expert review of anticancer therapy. 2024.","url":"https://pubmed.ncbi.nlm.nih.gov/38502143/"},{"pmid":"38981022","citation":"Wang Z, Li Y, Yang J. CircCFL1 Promotes TNBC Stemness and Immunoescape via Deacetylation-Mediated c-Myc Deubiquitylation to Facilitate Mutant TP53 Transcription.. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024.","url":"https://pubmed.ncbi.nlm.nih.gov/38981022/"},{"pmid":"38145448","citation":"Jin LL, Lu HJ, Shao JK. Relevance and mechanism of STAT3/miR-221-3p/Fascin-1 axis in EGFR TKI resistance of triple-negative breast cancer.. Molecular and cellular biochemistry. 2024.","url":"https://pubmed.ncbi.nlm.nih.gov/38145448/"},{"pmid":"38604999","citation":"Ma Y, Fang Z, Zhang H. PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway.. Cell death & disease. 2024.","url":"https://pubmed.ncbi.nlm.nih.gov/38604999/"},{"pmid":"40460322","citation":"Riaz F, Gruber JJ, Telli ML. New Treatment Approaches for Triple-Negative Breast Cancer.. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2025.","url":"https://pubmed.ncbi.nlm.nih.gov/40460322/"},{"pmid":"39572842","citation":"Jain A, Barge A, Parris CN. Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.. Oncogene. 2025.","url":"https://pubmed.ncbi.nlm.nih.gov/39572842/"},{"pmid":"38772416","citation":"Cheung A, Chenoweth AM, Johansson A. Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024.","url":"https://pubmed.ncbi.nlm.nih.gov/38772416/"},{"pmid":"39342122","citation":"Wu Z, Xiang H, Wang X. Integrating network pharmacology, molecular docking and experimental verification to explore the therapeutic effect and potential mechanism of nomilin against triple-negative breast cancer.. Molecular medicine (Cambridge, Mass.). 2024.","url":"https://pubmed.ncbi.nlm.nih.gov/39342122/"},{"pmid":"41505030","citation":"van der Noord VE, McLaughlin RP, Karuntu JS. Disrupting CDK9 activity suppresses triple-negative breast cancer and is enhanced by EGFR Inhibition.. Cellular oncology (Dordrecht, Netherlands). 2026.","url":"https://pubmed.ncbi.nlm.nih.gov/41505030/"},{"pmid":"39085861","citation":"Shi HX, Tao HT, He JJ. Targeting DKK1 enhances the antitumor activity of paclitaxel and alleviates chemotherapy-induced peripheral neuropathy in breast cancer.. Molecular cancer. 2024.","url":"https://pubmed.ncbi.nlm.nih.gov/39085861/"},{"pmid":"40619383","citation":"Xu J, Yang X, Shu P. FRMD8 inhibits tumor metastasis in BRCA1-associated TNBC by negatively regulating tmTNF-α.. Cellular & molecular biology letters. 2025.","url":"https://pubmed.ncbi.nlm.nih.gov/40619383/"},{"pmid":"39402579","citation":"Chen K, Wu Y, Xu L. Identification of the metabolic protein ATP5MF as a potential therapeutic target of TNBC.. Journal of translational medicine. 2024.","url":"https://pubmed.ncbi.nlm.nih.gov/39402579/"},{"pmid":"40806559","citation":"Mohiuddin TM, Sheng W, Zhang C. Multiplex Immunofluorescence Reveals Therapeutic Targets EGFR, EpCAM, Tissue Factor, and TROP2 in Triple-Negative Breast Cancer.. International journal of molecular sciences. 2025.","url":"https://pubmed.ncbi.nlm.nih.gov/40806559/"},{"pmid":"40192514","citation":"Li T, Wu R, Luo KQ. PCSK9 Promotes the Malignancy of Triple-negative Breast Cancer Cells by Reducing Cholesterol Levels at the Plasma Membrane to Activate EGFR and HER3.. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2025.","url":"https://pubmed.ncbi.nlm.nih.gov/40192514/"},{"pmid":"39531335","citation":"Cai YW, Liu CC, Zhang YW. MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer.. The Journal of clinical investigation. 2024.","url":"https://pubmed.ncbi.nlm.nih.gov/39531335/"},{"pmid":"39482441","citation":"Lo YL, Hong CJ, Wang CS. Modulating versatile pathways using a cleavable PEG shell and EGFR-targeted nanoparticles to deliver CRISPR-Cas9 and docetaxel for triple-negative breast cancer inhibition.. Archives of pharmacal research. 2024.","url":"https://pubmed.ncbi.nlm.nih.gov/39482441/"}],"citationCounts":{"38145448":6,"38502143":7,"38604999":9,"38605363":10,"38735837":13,"38772416":16,"38869741":17,"38900236":81,"38981022":20,"39085861":14,"39342122":13,"39402579":2,"39415210":21,"39482441":2,"39500221":14,"39531335":6,"39572842":36,"39627505":8,"39817564":16,"40003864":10,"40192514":2,"40268132":14,"40460322":3,"40460510":5,"40590219":2,"40619383":1,"40806559":0,"40849803":1,"40944807":0,"41505030":0},"openAccessMap":{"38604999":"https://www.nature.com/articles/s41419-024-06502-2.pdf","38605363":"https://genomemedicine.biomedcentral.com/counter/pdf/10.1186/s13073-024-01327-2","38735837":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cas.16208","38772416":"https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-23-3110/3454004/ccr-23-3110.pdf","38869741":"https://link.springer.com/content/pdf/10.1007/s12094-024-03541-1.pdf","38981022":"https://doi.org/10.1002/advs.202404628","39085861":"https://molecular-cancer.biomedcentral.com/counter/pdf/10.1186/s12943-024-02067-y","39415210":"https://doi.org/10.1186/s12943-024-02150-4","39482441":"https://doi.org/10.1007/s12272-024-01514-0","39572842":"https://doi.org/10.1038/s41388-024-03227-6","40003864":"https://doi.org/10.3390/ijms26041396"},"leadingResearchers":[{"name":"Jianping Chen","paperCount":1,"totalCitations":81,"avgCitations":81,"topPaper":{"pmid":"38900236","title":"Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.","year":"2024","citationCount":81},"role":"Senior Researcher"},{"name":"Kumar Ganesan","paperCount":1,"totalCitations":81,"avgCitations":81,"topPaper":{"pmid":"38900236","title":"Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.","year":"2024","citationCount":81},"role":"Active Contributor"},{"name":"Cong Xu","paperCount":1,"totalCitations":81,"avgCitations":81,"topPaper":{"pmid":"38900236","title":"Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.","year":"2024","citationCount":81},"role":"Active Contributor"},{"name":"Jianming Wu","paperCount":1,"totalCitations":81,"avgCitations":81,"topPaper":{"pmid":"38900236","title":"Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.","year":"2024","citationCount":81},"role":"Active Contributor"},{"name":"Bing Du","paperCount":1,"totalCitations":81,"avgCitations":81,"topPaper":{"pmid":"38900236","title":"Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.","year":"2024","citationCount":81},"role":"Active Contributor"},{"name":"Qingqing Liu","paperCount":1,"totalCitations":81,"avgCitations":81,"topPaper":{"pmid":"38900236","title":"Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.","year":"2024","citationCount":81},"role":"Active Contributor"},{"name":"Yue Sui","paperCount":1,"totalCitations":81,"avgCitations":81,"topPaper":{"pmid":"38900236","title":"Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.","year":"2024","citationCount":81},"role":"Active Contributor"},{"name":"Hailin Tang","paperCount":1,"totalCitations":81,"avgCitations":81,"topPaper":{"pmid":"38900236","title":"Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.","year":"2024","citationCount":81},"role":"Active Contributor"},{"name":"Cailu Song","paperCount":2,"totalCitations":95,"avgCitations":48,"topPaper":{"pmid":"38900236","title":"Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.","year":"2024","citationCount":81},"role":"Active Contributor"},{"name":"Jinhui Zhang","paperCount":2,"totalCitations":95,"avgCitations":48,"topPaper":{"pmid":"38900236","title":"Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.","year":"2024","citationCount":81},"role":"Active Contributor"}],"recommendedPapers":[],"totalPapersUsed":12,"audience":"researcher","audienceLabel":"Researcher-focused view","generatedAtIso":"2026-01-12T03:41:52.736Z","analysisTime":"161815ms","dataSource":{"genes":"Ensembl + ClinVar + UniProt + GO","pathways":"KEGG","literature":"PubMed + Semantic Scholar","interactions":"STRING + BioGRID","clinical":"Open Targets + DisGeNET","drugs":"ChEMBL (2.4M+ compounds) + DrugBank + DGIdb (40K+ interactions)","ai":"DeepSeek V3","hypothesisEngine":"GaiaLab AI (Graph Neural Networks + Probabilistic Reasoning)"},"databaseStats":{"totalDatabases":13,"bioactiveCompounds":"2.4M+","databases":["UniProt","KEGG","PubMed","STRING","Open Targets","BioGRID","Gene Ontology","Ensembl","DisGeNET","ClinVar","ChEMBL","DrugBank","Semantic Scholar"]},"disclaimer":"AI-generated insights for research purposes. Requires expert validation. Not medical advice.","cacheStats":{"cached":false,"timestamp":1768189474570,"hitRate":"0.0"}}